VKTX in the 13F filings
Viking Therapeutics Inc · CUSIP 92686J106
- Quarter end
- 31 Dec 2023
- the date the book describes
- Filed
- 14 Feb 2024
- latest of these filings; the earliest 14 Feb 2024
- Managers listing it
- 2
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q3 2023 and Q4 2023; 1 listed it in both
- Shares listed
- 7,388,635
- combined, among listed positions
- Reported value
- $138m
- combined, at the quarter end
Among the 93 comparable managers: 2 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing VKTX in Q4 2023
2 of 2 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Viking Global Investors LP | 5,145,112 | $96m | 0.35% | Added | +571,796 | 14 Feb 2024 (the filing on sec.gov) |
| Balyasny Asset Management LLC | 2,243,523 | $42m | 0.08% | Added | n.a. | 14 Feb 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Viking Global Investors LPexisting position · 5,145,112 shares now+571,796
Reductions
No reduction among listed positions.
New positions and exits
New (0)
No new position among listed positions.
Exited (1)
- Moore Capital Management LPwas $554k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2018 | 1 | $949k | n.a. | n.a. |
| Q3 2018 | 3 | $20m | n.a. | n.a. |
| Q4 2018 | 1 | $161k | n.a. | n.a. |
| Q1 2019 | 1 | $6.5m | n.a. | n.a. |
| Q2 2019 | 2 | $5.4m | n.a. | n.a. |
| Q3 2019 | 1 | $751k | n.a. | n.a. |
| Q4 2020 | 1 | $112k | n.a. | n.a. |
| Q1 2021 | 1 | $245k | n.a. | n.a. |
| Q2 2021 | 2 | $1.0m | n.a. | n.a. |
| Q3 2021 | 2 | $769k | n.a. | n.a. |
| Q4 2021 | 1 | $627k | n.a. | n.a. |
| Q1 2022 | 1 | $290k | n.a. | n.a. |
| Q2 2022 | 1 | $849k | n.a. | n.a. |
| Q3 2022 | 2 | $3.5m | n.a. | n.a. |
| Q4 2022 | 3 | $13m | n.a. | n.a. |
| Q1 2023 | 4 | $71m | n.a. | n.a. |
| Q2 2023 | 1 | $57m | n.a. | n.a. |
| Q3 2023 | 3 | $54m | n.a. | n.a. |
| Q4 2023 | 2 | $138m | 2 | 1 |
| Q1 2024 | 7 | $1.6bn | 5 | 2 |
| Q2 2024 | 5 | $961m | 5 | 1 |
| Q3 2024 | 5 | $1.1bn | 2 | 3 |
| Q4 2024 | 6 | $794m | 4 | 3 |
| Q1 2025 | 4 | $61m | 4 | 2 |
| Q2 2025 | 3 | $72m | 3 | 0 |
| Q3 2025 | 6 | $117m | 6 | 0 |
| Q4 2025 | 6 | $202m | 18 | 9 |
| Q1 2026 | 2 | $156m | 10 | 18 |
| Q2 2026 | 4 | $183m | 20 | 6 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
VKTX and LLY →VKTX and JNJ →VKTX and VRTX →Choose a stock to compare with VKTX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own VKTX, latest filings →Back to the 13F Explorer →